U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Low Grade Astrocytoma

MedGen UID:
1791071
•Concept ID:
C5554630
•
Neoplastic Process

Definition

Low grade astrocytoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Low Grade Astrocytoma

Professional guidelines

PubMed

Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience.
Susam-Sen H, Varan A, Bajin İ, Göçmen R, Aydın B, Yalcin B, Kurucu N, Kutluk T, Bayhan T, Akyuz C
Naunyn Schmiedebergs Arch Pharmacol 2021 Aug;394(8):1769-1777. Epub 2021 Jun 21 doi: 10.1007/s00210-021-02109-y. PMID: 34151393
Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy.
Voynov G, Kaufman S, Hong T, Pinkerton A, Simon R, Dowsett R
Am J Clin Oncol 2002 Dec;25(6):606-11. doi: 10.1097/00000421-200212000-00017. PMID: 12478010
Epilepsy and gliomas: incidence and treatment in 119 patients.
Pace A, Bove L, Innocenti P, Pietrangeli A, Carapella CM, Oppido P, Raus L, Occhipinti E, Jandolo B
J Exp Clin Cancer Res 1998 Dec;17(4):479-82. PMID: 10089071

Recent clinical studies

Etiology

Low-grade glioma of the temporal lobe and tumor-related epilepsy in children.
Baticulon RE, Wittayanakorn N, Maixner W
Childs Nerv Syst 2024 Oct;40(10):3085-3098. Epub 2024 May 24 doi: 10.1007/s00381-024-06468-8. PMID: 38789690
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, von Bubnoff N, van Linde ME, Lai A, Prager GW, Campone M, Fasolo A, Lopez-Martin JA, Kim TM, Mason WP, Hofheinz RD, Blay JY, Cho DC, Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran P, Gasal E, Subbiah V
Lancet Oncol 2022 Jan;23(1):53-64. Epub 2021 Nov 24 doi: 10.1016/S1470-2045(21)00578-7. PMID: 34838156
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Qayed M, Cash T, Tighiouart M, MacDonald TJ, Goldsmith KC, Tanos R, Kean L, Watkins B, Suessmuth Y, Wetmore C, Katzenstein HM
Pediatr Blood Cancer 2020 Apr;67(4):e28134. Epub 2019 Dec 25 doi: 10.1002/pbc.28134. PMID: 31876107
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Trametinib for progressive pediatric low-grade gliomas.
Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D, Legault G, Crevier L, Weil A, Farmer JP, Jabado N, Perreault S
J Neurooncol 2018 Nov;140(2):435-444. Epub 2018 Aug 10 doi: 10.1007/s11060-018-2971-9. PMID: 30097824

Diagnosis

Low-grade glioma of the temporal lobe and tumor-related epilepsy in children.
Baticulon RE, Wittayanakorn N, Maixner W
Childs Nerv Syst 2024 Oct;40(10):3085-3098. Epub 2024 May 24 doi: 10.1007/s00381-024-06468-8. PMID: 38789690
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Qayed M, Cash T, Tighiouart M, MacDonald TJ, Goldsmith KC, Tanos R, Kean L, Watkins B, Suessmuth Y, Wetmore C, Katzenstein HM
Pediatr Blood Cancer 2020 Apr;67(4):e28134. Epub 2019 Dec 25 doi: 10.1002/pbc.28134. PMID: 31876107
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Trametinib for progressive pediatric low-grade gliomas.
Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D, Legault G, Crevier L, Weil A, Farmer JP, Jabado N, Perreault S
J Neurooncol 2018 Nov;140(2):435-444. Epub 2018 Aug 10 doi: 10.1007/s11060-018-2971-9. PMID: 30097824
BCR gene disruption in a pilomyxoid astrocytoma.
Meléndez B, Fiaño C, Ruano Y, Hernández-Moneo JL, Mollejo M, Martinez P
Neuropathology 2006 Oct;26(5):442-6. doi: 10.1111/j.1440-1789.2006.00712.x. PMID: 17080723

Therapy

Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, von Bubnoff N, van Linde ME, Lai A, Prager GW, Campone M, Fasolo A, Lopez-Martin JA, Kim TM, Mason WP, Hofheinz RD, Blay JY, Cho DC, Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran P, Gasal E, Subbiah V
Lancet Oncol 2022 Jan;23(1):53-64. Epub 2021 Nov 24 doi: 10.1016/S1470-2045(21)00578-7. PMID: 34838156
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Qayed M, Cash T, Tighiouart M, MacDonald TJ, Goldsmith KC, Tanos R, Kean L, Watkins B, Suessmuth Y, Wetmore C, Katzenstein HM
Pediatr Blood Cancer 2020 Apr;67(4):e28134. Epub 2019 Dec 25 doi: 10.1002/pbc.28134. PMID: 31876107
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.
Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B, Sa JK, Cho HJ, Her NG, Zhang C, Zhao Z, Zhang Y, Zeng F, Wu F, Kang X, Liu Y, Qian Z, Wang Z, Huang R, Wang Q, Zhang W, Qiu X, Li W, Nam DH, Fan X, Wang J, Jiang T
Cell 2018 Nov 29;175(6):1665-1678.e18. Epub 2018 Oct 18 doi: 10.1016/j.cell.2018.09.038. PMID: 30343896
Interstitial 5-ALA photodynamic therapy and glioblastoma: Preclinical model development and preliminary results.
Tetard MC, Vermandel M, Leroy HA, Leroux B, Maurage CA, Lejeune JP, Mordon S, Reyns N
Photodiagnosis Photodyn Ther 2016 Mar;13:218-224. Epub 2015 Jul 23 doi: 10.1016/j.pdpdt.2015.07.169. PMID: 26213327

Prognosis

Extra-temporal pediatric low-grade gliomas and epilepsy.
Hinojosa J, Becerra V, Candela-Cantó S, Alamar M, Culebras D, Valencia C, Valera C, Rumiá J, Muchart J, Aparicio J
Childs Nerv Syst 2024 Oct;40(10):3309-3327. Epub 2024 Aug 27 doi: 10.1007/s00381-024-06573-8. PMID: 39191974
Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas.
Han M, Sun Y, Zhao W, Xiang G, Wang X, Jiang Z, Xue Z, Zhou W
Front Immunol 2022;13:1025286. Epub 2022 Oct 20 doi: 10.3389/fimmu.2022.1025286. PMID: 36341396Free PMC Article
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.
Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B, Sa JK, Cho HJ, Her NG, Zhang C, Zhao Z, Zhang Y, Zeng F, Wu F, Kang X, Liu Y, Qian Z, Wang Z, Huang R, Wang Q, Zhang W, Qiu X, Li W, Nam DH, Fan X, Wang J, Jiang T
Cell 2018 Nov 29;175(6):1665-1678.e18. Epub 2018 Oct 18 doi: 10.1016/j.cell.2018.09.038. PMID: 30343896
BCR gene disruption in a pilomyxoid astrocytoma.
Meléndez B, Fiaño C, Ruano Y, Hernández-Moneo JL, Mollejo M, Martinez P
Neuropathology 2006 Oct;26(5):442-6. doi: 10.1111/j.1440-1789.2006.00712.x. PMID: 17080723

Clinical prediction guides

Extra-temporal pediatric low-grade gliomas and epilepsy.
Hinojosa J, Becerra V, Candela-Cantó S, Alamar M, Culebras D, Valencia C, Valera C, Rumiá J, Muchart J, Aparicio J
Childs Nerv Syst 2024 Oct;40(10):3309-3327. Epub 2024 Aug 27 doi: 10.1007/s00381-024-06573-8. PMID: 39191974
Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience.
Susam-Sen H, Varan A, Bajin İ, Göçmen R, Aydın B, Yalcin B, Kurucu N, Kutluk T, Bayhan T, Akyuz C
Naunyn Schmiedebergs Arch Pharmacol 2021 Aug;394(8):1769-1777. Epub 2021 Jun 21 doi: 10.1007/s00210-021-02109-y. PMID: 34151393
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Qayed M, Cash T, Tighiouart M, MacDonald TJ, Goldsmith KC, Tanos R, Kean L, Watkins B, Suessmuth Y, Wetmore C, Katzenstein HM
Pediatr Blood Cancer 2020 Apr;67(4):e28134. Epub 2019 Dec 25 doi: 10.1002/pbc.28134. PMID: 31876107
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M
Lancet Oncol 2019 Jul;20(7):1011-1022. Epub 2019 May 28 doi: 10.1016/S1470-2045(19)30277-3. PMID: 31151904Free PMC Article
Trametinib for progressive pediatric low-grade gliomas.
Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, Sinnett D, Legault G, Crevier L, Weil A, Farmer JP, Jabado N, Perreault S
J Neurooncol 2018 Nov;140(2):435-444. Epub 2018 Aug 10 doi: 10.1007/s11060-018-2971-9. PMID: 30097824

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...